Analysts Set Oscar Health, Inc. (NYSE:OSCR) Price Target at $22.93

Oscar Health, Inc. (NYSE:OSCR) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $22.93.

Several brokerages have recently weighed in on OSCR. Piper Sandler restated an “overweight” rating and set a $28.00 price objective on shares of Oscar Health in a research report on Tuesday, September 10th. Bank of America lowered Oscar Health from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $21.00 to $13.50 in a report on Wednesday, November 6th. Finally, UBS Group started coverage on Oscar Health in a report on Monday, October 7th. They issued a “neutral” rating and a $23.00 target price for the company.

Oscar Health Stock Up 3.4 %

Oscar Health stock opened at $16.84 on Friday. The stock has a market cap of $4.16 billion, a PE ratio of -280.62 and a beta of 1.67. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.73 and a quick ratio of 0.73. The stock’s fifty day moving average is $17.57 and its two-hundred day moving average is $18.10. Oscar Health has a 1-year low of $7.29 and a 1-year high of $23.79.

Oscar Health (NYSE:OSCR) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.02). The business had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.33 billion. Oscar Health had a return on equity of 2.79% and a net margin of 0.35%. Oscar Health’s revenue was up 68.3% on a year-over-year basis. During the same period last year, the business posted ($0.29) EPS. On average, sell-side analysts expect that Oscar Health will post -0.01 EPS for the current fiscal year.

Insider Activity at Oscar Health

In other Oscar Health news, insider Mario Schlosser sold 3,198 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $17.99, for a total value of $57,532.02. Following the transaction, the insider now directly owns 76,982 shares of the company’s stock, valued at approximately $1,384,906.18. The trade was a 3.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Ranmali Bopitiya sold 36,175 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $17.99, for a total transaction of $650,788.25. Following the transaction, the executive vice president now owns 251,885 shares of the company’s stock, valued at approximately $4,531,411.15. The trade was a 12.56 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have purchased 1,055,478 shares of company stock worth $14,432,852 and have sold 194,569 shares worth $3,433,319. 25.11% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oscar Health

A number of institutional investors have recently added to or reduced their stakes in OSCR. Vanguard Group Inc. boosted its stake in shares of Oscar Health by 2.4% in the first quarter. Vanguard Group Inc. now owns 14,582,762 shares of the company’s stock valued at $216,846,000 after buying an additional 337,850 shares in the last quarter. State Street Corp lifted its holdings in Oscar Health by 6.0% in the third quarter. State Street Corp now owns 5,132,802 shares of the company’s stock valued at $108,867,000 after acquiring an additional 291,335 shares during the period. Geode Capital Management LLC boosted its position in shares of Oscar Health by 11.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,339,640 shares of the company’s stock worth $92,062,000 after purchasing an additional 455,205 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Oscar Health by 153.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,978,152 shares of the company’s stock worth $59,156,000 after purchasing an additional 2,409,160 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Oscar Health by 31.7% during the 2nd quarter. Renaissance Technologies LLC now owns 3,886,100 shares of the company’s stock worth $61,478,000 after purchasing an additional 934,600 shares during the period. Hedge funds and other institutional investors own 75.70% of the company’s stock.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.